Research programme: autoimmune disorder therapeutics - Ginkgo Bioworks/Microba Life Sciences
Latest Information Update: 28 Jul 2026
At a glance
- Originator Microba Life Sciences
- Developer Ginkgo Pharma; Microba Life Sciences
- Class Antirheumatics; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Psoriatic arthritis; Systemic lupus erythematosus
Most Recent Events
- 28 Jul 2026 No recent reports of development identified for research development in Autoimmune-disorders in Australia
- 28 Jul 2026 No recent reports of development identified for research development in Autoimmune-disorders in China
- 28 Jul 2026 No recent reports of development identified for research development in Psoriatic-arthritis in Australia